ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Wolchok Explains the Future of Ipilimumab

Jedd D. Wolchok, MD, PhD
Published: Friday, Jun 17, 2011

Jedd D. Wolchok, MD, PhD from Memorial Sloan-Kettering Cancer Center explains the future of ipilimumab.

Dr. Wolchok says that, in general, ipilimumab releases a breaking mechanism on the immune system. He says it's versatile in that it could have activity in diseases other than melanoma because it doesn't specifically release an immune response to melanoma. It does release an immune response to melanoma, but there are ongoing studies using ipilimumab in prostate cancer and there have been smaller experiences in ovary cancer and kidney cancer. This brings up the possibility that it could be applied in other disease settings.
Jedd D. Wolchok, MD, PhD from Memorial Sloan-Kettering Cancer Center explains the future of ipilimumab.

Dr. Wolchok says that, in general, ipilimumab releases a breaking mechanism on the immune system. He says it's versatile in that it could have activity in diseases other than melanoma because it doesn't specifically release an immune response to melanoma. It does release an immune response to melanoma, but there are ongoing studies using ipilimumab in prostate cancer and there have been smaller experiences in ovary cancer and kidney cancer. This brings up the possibility that it could be applied in other disease settings.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x